Liver Cancer Drugs Market

Liver Cancer Drugs Market by Therapeutic Classes (Targeted Therapy and Immunotherapy), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-982
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 158
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global liver cancer drugs market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the presence of strong pipeline, availability of novel drugs, rising awareness among people, growing incidence of liver cancer.

Liver Cancer Drugs Market Key Takeaways

Liver cancer is a cancer that starts in the liver cells. It is a type of chronic disorder which is progressive and life-threatening. Liver cancer is the fifth largest prevalent cancer around the world. There are several types of liver cancer such as primary hepatic cancer and metastatic cancer. In primary hepatic cancer, it begins in hepatocyte cells. In metastatic cancer, it spreads to the liver from other parts of the body. Liver cancer holds around 9% of overall cancer deaths. Around 780,500 new cases were diagnosed in 2012 and 745,500 deaths were occurred because of liver cancer. Due to poor survival rate and aggressive nature the primary liver cancer is one of the most important public health issues.

Hepatocellular carcinomas (HCCs) hold majority of primary liver cancers. A substantial number of etiological factors of liver cancer are hepatitis infection and cirrhosis. These factors present a strong prospect for decreasing the incidences and mortality by using prevention strategies which includes hepatitis immunization and lifestyle modification. Even most systemic drugs are not efficient for the treatment of Liver cancer. Hence, research and developments are majorly focusing on molecular pathways involved in hepatocarcinogenesis.

Liver cancer treatment market is increasing with rising first-in-class developments in novel therapies. Small molecules represent the largest group of drug products in development and licensing deals, after monoclonal antibodies. Huge portion of pipeline products target components of dysfunctional signaling pathway. Innovative treatment methods including RNA interference technology (RNAi) or oncolytic viruses have achieved important traction in the field.

Market Trends, Drivers, Restraints, and Opportunities

  • Growing prevalence of liver cancer and availability of novel drugs are major factors responsible for the growth of the market over the forecast period.
  • Increasing investment on research and development sector and rising development of novel therapies are expected to fuel the market growth in the coming years.
  • Rising initiatives by government and presence of strong pipeline are projected to drive the expansion of the market.
  • Increasing awareness about cancer among people is factor that can propel the market growth during the forecast period.
  • Growing geriatric population and changing lifestyle are anticipated to push the market growth in the coming years.
  • High cost of cancer therapies and side effects of drugs are major factor responsible for hampering the growth of the market in the coming years.
  • Stringent regulation is projected to impede the market expansion over the forecast period.

Scope of the Report

The report on the global liver cancer drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Liver Cancer Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Therapeutic Classes (Targeted Therapy and Immunotherapy)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck; AstraZeneca; Eli Lilly; Amgen; Pfizer Inc.; Novartis AG; and SillaJen


Market Segment Insights

Targeted therapy segment is projected to hold key market share
Based on therapeutic classes, the liver cancer drugs market is bifurcated into targeted therapy and immunotherapy. The targeted therapy segment is expected to hold a key share of the market during the forecast period. The best treatment for HCC is partial surgical resection. The risk of fatal complications such as liver failure increases due to resection of cirrhotic livers. The relapse rate after this surgery is high. However, the rate of survival is improved significantly. Nexavar is the only approved targeted therapy for the advanced HCC patients.

On the other hand, the immunotherapy segment is anticipated to expand at a rapid pace during the forecast period. Immunotherapy fights with cancer cells by using human immune system. In this type several drugs are present across the globe. The immunotherapy segment comprises of checkpoint inhibitors and targeted antibodies. Increasing research and development, rising awareness about cancer therapeutics among people, and advantages of immunotherapy are expected to drive the growth of the segment.

Liver Cancer Drugs Market By Therapeutic Classes

North America is expected to dominate the market
On the basis of regions, the liver cancer drugs market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to launch of novel products, increasing adoption of novel therapeutics, and presence of a large target population. In U.S., rising R&D activities are anticipated to drive the regional market growth. The Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) and bevacizumab (Avastin) in May 2020. This approval was for initial treatment of people having liver cancer which is spread and can’t be treated with surgery.

However, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to rising incidences of liver cancer, presence of huge base of targeted population, and strong unmet clinical needs.

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Liver Cancer Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Liver Cancer Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Liver Cancer Drugs Market - Supply Chain
  4.5. Global Liver Cancer Drugs Market Forecast
     4.5.1. Liver Cancer Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Liver Cancer Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Liver Cancer Drugs Market Absolute $ Opportunity
5. Global Liver Cancer Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Liver Cancer Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Liver Cancer Drugs Demand Share Forecast, 2019-2026
6. North America Liver Cancer Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Liver Cancer Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Liver Cancer Drugs Demand Share Forecast, 2019-2026
7. Latin America Liver Cancer Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Liver Cancer Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Liver Cancer Drugs Demand Share Forecast, 2019-2026
8. Europe Liver Cancer Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Liver Cancer Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Liver Cancer Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Liver Cancer Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Liver Cancer Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Liver Cancer Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Liver Cancer Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Liver Cancer Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Liver Cancer Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Liver Cancer Drugs Market: Market Share Analysis
  11.2. Liver Cancer Drugs Distributors and Customers
  11.3. Liver Cancer Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Bayer Bristol-Myers Squibb Eisai Exelixis Merck AstraZeneca Eli Lilly Amgen  
Segments Covered in the Report
The global liver cancer drugs market has been segmented on the basis of

Therapeutic Classes
  • Targeted Therapy
  • Immunotherapy
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Bayer
  • Bristol-Myers Squibb
  • Eisai
  • Exelixis
  • Merck
  • AstraZeneca
  • Eli Lilly
  • Amgen
  • Pfizer Inc.
  • Novartis AG
  • SillaJen
Key players competing in the liver cancer drugs market are Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck; AstraZeneca; Eli Lilly; Amgen; Pfizer Inc.; Novartis AG; and SillaJen. Major market players are adopting several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
Liver Cancer Drugs Market By Key Players

Buy Report